Jnj-54175446
Depressive Disorder, Major
CCTU-CoreSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
235 Active assets in the Depressive Disorder, Major cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Zelapar Corium Innovations, Inc. | Phase 4 | BBB |
Risperdal Johns Hopkins University | Phase 4 | BBB |
S-Ketamine Janssen Research & Development, LLC | Phase 4 | BBB |
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
Vortioxetine Mayo Clinic | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Jnj-54175446 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →